Not recruiting
Migraine
Not recruitingInvestigational
Study on Atogepant for Preventing Menstrual Migraine in Women
Investigational
Countries:
Germany
Germany- Participants:18–64 years
- Substances:Atogepant
- Sponsor:AbbVie Deutschland GmbH & Co. KG
Back to GermanyClinical trials in Bielefeld – page 9
147 clinical trials in Bielefeld, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Bielefeld at a glance
147
clinical trials
- Research sites1
Not recruiting
Epilepsy
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Levetiracetam XR for Patients with Drug-Resistant Partial Onset Epilepsy
Registered drug
- Disease:Epilepsy
- Substances:Levetiracetam
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Levetiracetam
- Sponsor:Neuraxpharm Pharmaceuticals S.L.
Not recruiting
Generalised tonic-clonic seizure+1
Not recruitingInvestigationalNo placebo
Study on PRAX-628 for Adults with Focal Onset or Generalized Tonic-Clonic Seizures
InvestigationalNo placebo
- Disease:Generalised tonic-clonic seizurePartial seizures
- Substances:Prax-628
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Prax-628
- Sponsor:Praxis Precision Medicines Inc.
Not recruiting
Multiple sclerosis
Not recruitingInvestigational
Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis
Investigational
- Disease:Multiple sclerosis
- Substances:Frexalimab
Countries:Germany
Germany- Participants:18–64 years
- Substances:Frexalimab
- Sponsor:Sanofi-Aventis Recherche & Developpement
Not recruiting
Multiple sclerosis relapse
Not recruitingRegistered drugNo placebo
Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis
Registered drugNo placebo
- Disease:Multiple sclerosis relapse
- Substances:OfatumumabA/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type)+42
Countries:Germany
Germany- Participants:18–64 years
- Substances:Ofatumumab
- Sponsor:Novartis Pharma AG
Not recruiting
Plasma cell myeloma
Not recruitingRegistered drugNo placebo
Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:BortezomibDexamethasone+2
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Universitaetsklinikum Heidelberg AöR
Not recruiting
CDKL5 deficiency disorder
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Fenfluramine Hydrochloride for Patients with CDKL5 Deficiency Disorder
Registered drug
- Disease:CDKL5 deficiency disorder
- Substances:Fenfluramine Hydrochloride
Countries:Germany
Germany- Participants:0–17 years · 18–64 years
- Substances:Fenfluramine Hydrochloride
- Sponsor:Zogenix International Limited
Not recruiting
Gastrooesophageal cancer
Not recruitingRegistered drugNo placebo
Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma
Registered drugNo placebo
- Disease:Gastrooesophageal cancer
- Substances:AtezolizumabDocetaxel+3
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Not recruiting
Breast cancer+7
Not recruitingRegistered drugNo placebo
Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment
Registered drugNo placebo
- Disease:Breast cancerTriple negative breast cancer+6
- Substances:CapecitabineCarboplatin+2
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:GBG Forschungs GmbH
Not recruiting
Partial seizures
Not recruitingInvestigational
Study on the Safety and Effectiveness of Azetukalner for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications
Investigational
- Disease:Partial seizures
- Substances:Azetukalner
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Azetukalner
- Sponsor:Xenon Pharmaceuticals Inc.
Not recruiting
Partial seizures
Not recruitingInvestigational
Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy
Investigational
- Disease:Partial seizures
- Substances:Bhv-7000
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Bhv-7000
- Sponsor:Biohaven Therapeutics Ltd.
Not recruiting
Plasma cell myeloma
Not recruitingRegistered drugNo placebo
Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients
Registered drugNo placebo
- Disease:Plasma cell myeloma
- Substances:CarfilzomibIsatuximab+1
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Carfilzomib
- Sponsor:University Medical Center Hamburg-Eppendorf
Other cities in Germany
The busiest research cities in the country
Clinical research in Bielefeld
What the registry says about research in the country
01 Oncology Research
Extensive studies focusing on breast cancer treatments, including innovative therapies for HR-positive and HER2-negative variants. Research extends to gastric cancer and advanced ovarian cancer treatments.
- Early-stage breast cancer therapies
- Gastroesophageal junction cancer treatments
- Ovarian cancer maintenance therapy
Novel combinations of targeted therapies and immunotherapies are being evaluated for improved patient outcomes.
02 Neurological Disorders
Comprehensive research into epilepsy and seizure disorders, with particular focus on both focal onset and generalized seizures. Studies include investigations of new treatments for Dravet Syndrome.
- Seizure frequency reduction therapies
- Extended-release anticonvulsant medications
- Migraine prevention treatments
Emphasis on developing long-term treatment solutions for various seizure types.
03 Dermatology Studies
Investigation of treatments for plaque psoriasis and preventive measures for atopic dermatitis in high-risk populations. Focus on both adult and pediatric patients.
- Moderate to severe psoriasis treatments
- Preventive dermatological care
- Long-term safety evaluations
Studies aim to develop effective management strategies for chronic skin conditions.